Sanne C F A Huijberts1, Mirjam C Boelens2, Rene Bernards3, Frans L Opdam4. 1. Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.huijberts@nki.nl. 2. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. f.opdam@nki.nl.
Abstract
BACKGROUND: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAFV600E mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response and/or acquired resistance in these patients receiving therapies consisting of a backbone of BRAF and EGFR inhibition. METHODS: This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway. We examined tumour tissue for genetic alterations at baseline, during treatment and at progression. RESULTS: In total, 37 patients were included in this cohort. Genetic alterations in EGFR and in PIK3CA are associated with non-response. A greater fraction of non-responders (75%) versus responders (46%) had at least one genetic alteration in other genes than TP53, APC or BRAF. Secondary resistance mutations (n = 16 patients) were observed most frequently in the PI3K pathway (n = 6) and in receptor tyrosine kinases (n = 4), leading to increased upstream signalling. CONCLUSIONS: Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance. By understanding these alterations, simultaneous or alternating treatments with targeted inhibitors might improve response duration.
BACKGROUND: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAFV600E mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response and/or acquired resistance in these patients receiving therapies consisting of a backbone of BRAF and EGFR inhibition. METHODS: This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway. We examined tumour tissue for genetic alterations at baseline, during treatment and at progression. RESULTS: In total, 37 patients were included in this cohort. Genetic alterations in EGFR and in PIK3CA are associated with non-response. A greater fraction of non-responders (75%) versus responders (46%) had at least one genetic alteration in other genes than TP53, APC or BRAF. Secondary resistance mutations (n = 16 patients) were observed most frequently in the PI3K pathway (n = 6) and in receptor tyrosine kinases (n = 4), leading to increased upstream signalling. CONCLUSIONS: Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance. By understanding these alterations, simultaneous or alternating treatments with targeted inhibitors might improve response duration.
Authors: David Barras; Edoardo Missiaglia; Pratyaksha Wirapati; Oliver M Sieber; Robert N Jorissen; Chris Love; Peter L Molloy; Ian T Jones; Stephen McLaughlin; Peter Gibbs; Justin Guinney; Iris M Simon; Arnaud D Roth; Fred T Bosman; Sabine Tejpar; Mauro Delorenzi Journal: Clin Cancer Res Date: 2016-06-27 Impact factor: 12.531
Authors: Ryan B Corcoran; Thierry André; Chloe E Atreya; Jan H M Schellens; Takayuki Yoshino; Johanna C Bendell; Antoine Hollebecque; Autumn J McRee; Salvatore Siena; Gary Middleton; Kei Muro; Michael S Gordon; Josep Tabernero; Rona Yaeger; Peter J O'Dwyer; Yves Humblet; Filip De Vos; A Scott Jung; Jan C Brase; Savina Jaeger; Severine Bettinger; Bijoyesh Mookerjee; Fatima Rangwala; Eric Van Cutsem Journal: Cancer Discov Date: 2018-02-05 Impact factor: 39.397
Authors: Robin M J M van Geel; Josep Tabernero; Elena Elez; Johanna C Bendell; Anna Spreafico; Martin Schuler; Takayuki Yoshino; Jean-Pierre Delord; Yasuhide Yamada; Martijn P Lolkema; Jason E Faris; Ferry A L M Eskens; Sunil Sharma; Rona Yaeger; Heinz-Josef Lenz; Zev A Wainberg; Emin Avsar; Arkendu Chatterjee; Savina Jaeger; Eugene Tan; Kati Maharry; Tim Demuth; Jan H M Schellens Journal: Cancer Discov Date: 2017-03-31 Impact factor: 39.397
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Daniele Oddo; Erin M Sennott; Ludovic Barault; Emanuele Valtorta; Sabrina Arena; Andrea Cassingena; Genny Filiciotto; Giulia Marzolla; Elena Elez; Robin M J M van Geel; Alice Bartolini; Giovanni Crisafulli; Valentina Boscaro; Jason T Godfrey; Michela Buscarino; Carlotta Cancelliere; Michael Linnebacher; Giorgio Corti; Mauro Truini; Giulia Siravegna; Julieta Grasselli; Margherita Gallicchio; René Bernards; Jan H M Schellens; Josep Tabernero; Jeffrey A Engelman; Andrea Sartore-Bianchi; Alberto Bardelli; Salvatore Siena; Ryan B Corcoran; Federica Di Nicolantonio Journal: Cancer Res Date: 2016-06-16 Impact factor: 12.701
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Eric Van Cutsem; Sanne Huijberts; Axel Grothey; Rona Yaeger; Pieter-Jan Cuyle; Elena Elez; Marwan Fakih; Clara Montagut; Marc Peeters; Takayuki Yoshino; Harpreet Wasan; Jayesh Desai; Fortunato Ciardiello; Ashwin Gollerkeri; Janna Christy-Bittel; Kati Maharry; Victor Sandor; Jan H M Schellens; Scott Kopetz; Josep Tabernero Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: Aryana R Rasti; Amy Guimaraes-Young; Farrah Datko; Virginia F Borges; Dara L Aisner; Elena Shagisultanova Journal: JCO Precis Oncol Date: 2022-03